Literature DB >> 32633864

Identifying gaps across the cascade of care for the prevention of HBV mother-to-child transmission in Burkina Faso: Findings from the real world.

Alice N Guingané1, Alain Bougouma1, Roger Sombié1, Rachel King2, Nicolas Nagot2, Nicolas Meda3, Philippe Van de Perre2, Edouard Tuaillon2.   

Abstract

BACKGROUND: Prevention of mother-to-child transmission (PMTCT) is a challenge for controlling the hepatitis B epidemic. In Sub-Saharan countries, pilot interventions including the screening of pregnant women for HBsAg, implementation of anti-HBV therapy and infant immunization within 24 hours of life are initiated and need to be evaluated. This pilot study aimed to describe the cascade of care for hepatitis B PMTCT in a real life situation, and to identify sociodemographic factors associated with adequate management of pregnant women and infants.
METHOD: The study was conducted from October 1st, 2014 to February 28th, 2016 in the antenatal clinics (ANCV) of Baskuy district which comprises nine first-level public health centres. Univariate and multivariate logistic regression analysis were used to identify sociodemographic factors associated with the likelihood of retention in the cohort, HBV DNA testing, birth dose delivery and HBsAg testing of the children at 6 months of age; P ˂ .05 was selected as cut off for significance.
RESULTS: In this prospective cohort study, of 5200 pregnant women consulting for the antenatal visit, 2261 (43.5%) were proposed pre-test counselling and HBsAg screening and 2220 (98.2%) have agreed to screening. Among 1580 (71.2%) women that came back for the post-counselling interview, 75 were positive for HBsAg (4.8%), 73 (97.3% of the women provided HBsAg result) consented to medical consultation with hepatogastroenterologists and 53 (72.6%); performed the HBV DNA testing. Forty-seven out of 60 (78.3%; 65.8-87.9) children born alive were immunized for HBV within 24 hours of life. Retention in care was associated with the level of education of the infant's father, secondary school or higher was associated with a better retention in care of the women (OR: 6.6; P = .03).
CONCLUSION: Our study shows large gaps in HBV PMTCT. Resources for hepatitis B screening, care and prevention including universal access to the vaccine birth dose should be allocated to reduce infection in HBV exposed infants born in Burkina Faso.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Prenatal consultation; mother-to-child transmission; tenofovir; vaccination; viral hepatitis B

Mesh:

Substances:

Year:  2020        PMID: 32633864     DOI: 10.1111/liv.14592

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  3 in total

1.  Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study.

Authors:  Peyton Thompson; Camille E Morgan; Patrick Ngimbi; Kashamuka Mwandagalirwa; Noro L R Ravelomanana; Martine Tabala; Malongo Fathy; Bienvenu Kawende; Jérémie Muwonga; Pacifique Misingi; Charles Mbendi; Christophe Luhata; Ravi Jhaveri; Gavin Cloherty; Didine Kaba; Marcel Yotebieng; Jonathan B Parr
Journal:  Lancet Glob Health       Date:  2021-08-17       Impact factor: 26.763

2.  Screening for Hepatitis B in partners and children of women positive for surface antigen, Burkina Faso.

Authors:  Alice Nanelin Guingané; Rémi Kaboré; Yusuke Shimakawa; Eric Nagaonlé Somé; Dramane Kania; Amandine Pisoni; Nicolas Nagot; Rachel King; Roger Sombié; Nicolas Meda; Philippe Van de Perre; Edouard Tuaillon
Journal:  Bull World Health Organ       Date:  2022-02-22       Impact factor: 9.408

3.  Rapid Diagnostic Test for Hepatitis B Virus Viral Load Based on Recombinase Polymerase Amplification Combined with a Lateral Flow Read-Out.

Authors:  Charly Mayran; Vincent Foulongne; Philippe Van de Perre; Chantal Fournier-Wirth; Jean-Pierre Molès; Jean-François Cantaloube
Journal:  Diagnostics (Basel)       Date:  2022-03-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.